enGene Holdings Inc. (ENGN) 10-Year Financial Performance & Capital Metrics

ENGN • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutenGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Show more

Revenue $0
EBITDA -$123M -295.9%
Net Income $117M +312.7%
EPS (Diluted) -2.29 -56.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE 53.28% +266.7%
ROIC -67.43% -190.5%
Debt/Equity 0.19 +106.5%
Interest Coverage -41.14 -284.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 89 (top 11%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 14.5% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y1462.91%

TTM-19.1%

EPS CAGR

10Y-

5Y-

3Y-

TTM14.67%

ROCE

10Y Avg-11.15%

5Y Avg-11.15%

3Y Avg-14.08%

Latest-50.69%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Oct 2021	Oct 2022	Oct 2023	Oct 2024	Oct 2025
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	0	0	175K	323K	509K
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	0	-175K	-323K	-509K
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-	-	-0.85%	-0.58%
Operating Expenses+	15.87M	19.43M	25.89M	61.97M	123.17M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	3.15M	3.26M	9.43M	23.98M	28.68M
SG&A % of Revenue	-	-	-	-	-
Research & Development	12.46M	15.47M	16.46M	38.31M	94.48M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	253K	700K	0	-323K	0
Operating Income+	-15.87M	-1.83M	-26.06M	62.3M	-123.17M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	0.88%	-13.23%	3.39%	-2.98%
EBITDA+	-15.6M	-1.59M	-25.89M	62.62M	-122.66M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	0.9%	-15.24%	3.42%	-2.96%
D&A (Non-Cash Add-back)	272K	238K	175K	323K	509K
EBIT	-225K	30.73K	-94.95M	-52.36M	-114.31M
Net Interest Income+	-5M	-1.29M	-3.84M	7.62M	6.43M
Interest Income	25K	129K	1.12M	10.41M	9.43M
Interest Expense	5.02M	1.42M	4.95M	2.8M	2.99M
Other Income/Expense	-2.57M	1.86M	-73.84M	-7.14M	5.86M
Pretax Income+	-23.44M	30.73K	-99.9M	55.16M	-117.3M
Pretax Margin %	-	-	-	-	-
Income Tax+	4.9M	0	17K	-19K	0
Effective Tax Rate %	1%	1%	1%	-1%	-1%
Net Income+	-23.44M	30.73K	-99.92M	-55.14M	117.3M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	1%	-3252.87%	0.45%	3.13%
Net Income (Continuing)	-225.44K	30.73K	-99.92M	-55.14M	-117.3M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.01	0.00	-4.24	-1.46	-2.29
EPS Growth %	-	1.13%	-	0.66%	-0.57%
EPS (Basic)	-0.01	0.00	-4.24	-1.46	-2.29
Diluted Shares Outstanding	15.81M	15.81M	23.56M	44.64M	51.12M
Basic Shares Outstanding	15.81M	15.81M	23.56M	44.64M	51.12M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Oct 2021	Oct 2022	Oct 2023	Oct 2024	Oct 2025
Total Current Assets+	1.57M	511.8K	85.44M	247.36M	201.39M
Cash & Short-Term Investments	1.07M	314.15K	81.6M	238.4M	193.81M
Cash Only	1.07M	314.15K	81.52M	173M	50.15M
Short-Term Investments	0	0	76K	65.4M	143.66M
Accounts Receivable	0	0	2.34M	1.03M	2.23M
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	0	1.5M	7.93M	5.35M
Total Non-Current Assets+	129.88M	131.53M	1.52M	63.81M	20.08M
Property, Plant & Equipment	0	0	589K	2.91M	10.19M
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	129.67M	131.53M	70K	59.53M	8.52M
Other Non-Current Assets	209.05K	0	860K	1.37M	1.36M
Total Assets+	131.45M	132.04M	86.96M	311.17M	221.47M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	0%	-0.34%	2.58%	-0.29%
Total Current Liabilities+	327.45K	893.51K	5.26M	14.66M	31.98M
Accounts Payable	0	0	1.16M	1.41M	6.69M
Days Payables Outstanding	-	-	2.41K	1.59K	4.8K
Short-Term Debt	0	0	562K	1.12M	10.02M
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	327.45K	893.51K	2.69M	8.65M	11.2M
Current Ratio	4.79x	0.57x	16.25x	16.87x	6.30x
Quick Ratio	4.79x	0.57x	16.25x	16.87x	6.30x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	3.73M	3.73M	9.22M	23.9M	21.78M
Long-Term Debt	0	0	9.22M	22.47M	15.32M
Capital Lease Obligations	0	0	0	1.43M	6.46M
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	3.73M	0	0	0
Total Liabilities	4.05M	4.62M	14.47M	38.56M	53.76M
Total Debt+	0	0	9.78M	25.02M	31.8M
Net Debt	-1.07M	-314.15K	-71.74M	-147.98M	-18.36M
Debt / Equity	-	-	0.13x	0.09x	0.19x
Debt / EBITDA	-	-	-	0.40x	-
Net Debt / EBITDA	-	-	-	-2.36x	-
Interest Coverage	-3.16x	-1.29x	-5.26x	22.26x	-41.14x
Total Equity+	127.39M	127.42M	72.49M	272.61M	167.71M
Equity Growth %	-	0%	-0.43%	2.76%	-0.38%
Book Value per Share	8.06	8.06	3.08	6.11	3.28
Total Shareholders' Equity	127.39M	127.42M	72.49M	272.61M	167.71M
Common Stock	129.67M	131.53M	259.37M	509.81M	513.28M
Retained Earnings	-2.28M	-4.11M	-199.59M	-254.73M	-372.03M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	-1.02M	-1.42M	-888K
Minority Interest	0	0	0	0	0

Cash Flow

	Oct 2021	Oct 2022	Oct 2023	Oct 2024	Oct 2025
Cash from Operations+	-15.98M	-17.59M	-24.74M	-48.28M	-99.24M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-0.1%	-0.41%	-0.95%	-1.06%
Net Income	-23.44M	-24.46M	-99.92M	-55.14M	-117.3M
Depreciation & Amortization	272K	238K	175K	91K	-2.56M
Stock-Based Compensation	435K	116K	3.45M	5.32M	9.65M
Deferred Taxes	2.81M	3.97M	0	0	0
Other Non-Cash Items	4.97M	370K	72.07M	1.35M	1.24M
Working Capital Changes	-1.04M	2.17M	-517K	95K	9.74M
Change in Receivables	295K	143K	-1.01M	2.01M	-595K
Change in Inventory	0	0	0	0	0
Change in Payables	110K	-197K	373K	474K	4.94M
Cash from Investing+	-247K	-153K	-318K	-125.95M	-25.14M
Capital Expenditures	-248K	-153K	-318K	-925K	-1.49M
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	1K	0	0	0	0
Cash from Financing+	22.52M	27.97M	86.15M	265.72M	1.52M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	-144K	-423K	-4.01M	-7.49M	0
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-16.23M	-17.75M	-25.06M	-49.21M	-100.72M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-0.09%	-0.41%	-0.96%	-1.05%
FCF per Share	-1.03	-1.12	-1.06	-1.10	-1.97
FCF Conversion (FCF/Net Income)	0.68x	-572.54x	0.25x	0.88x	-0.85x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024	2025
Return on Equity (ROE)	-18.4%	0.02%	-99.96%	-31.96%	53.28%
Return on Invested Capital (ROIC)	-9.42%	-1.08%	-30.57%	74.53%	-67.43%
Debt / Equity	-	-	0.13x	0.09x	0.19x
Interest Coverage	-3.16x	-1.29x	-5.26x	22.26x	-41.14x
FCF Conversion	0.68x	-572.54x	0.25x	0.88x	-0.85x

Frequently Asked Questions

Growth & Financials

enGene Holdings Inc. (ENGN) grew revenue by 0.0% over the past year. Growth has been modest.

enGene Holdings Inc. (ENGN) reported a net loss of $65.7M for fiscal year 2025.

Dividend & Returns

enGene Holdings Inc. (ENGN) has a return on equity (ROE) of 53.3%. This is excellent, indicating efficient use of shareholder capital.

enGene Holdings Inc. (ENGN) had negative free cash flow of $100.7M in fiscal year 2025, likely due to heavy capital investments.

← Back to Screener